Trial Profile

A Phase Ib/II trial of lenzilumab for the prevention of neurotoxicity associated with CAR-T19 therapy

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 14 Dec 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CAR-T cell therapies (Primary) ; Lenzilumab (Primary)
Indications Drug toxicity
Focus Adverse reactions; Therapeutic Use
Sponsors Humanigen

Most Recent Events

30 Nov 2018 According to a Humanigen media release, this study is expected to be initiated in the coming months.
27 Feb 2018 According to a Humanigen media release, the company expects to begin this study in the second quarter of 2018
27 Dec 2017 New trial record

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com